Franklin Rosenfeldt

Prof. Franklin Rosenfeldt

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2019 in Expert Review of Clinical Pharmacology
Verified
Journal Article
Closed access
BTBrendan Tan
Brendan Tan
FRFranklin Rosenfeldt
Franklin Rosenfeldt
RORuchong Ou
Ruchong Ou
CSCon Stough
Con Stough
Introduction: Statin drugs have become the most highly prescribed drugs for cardiovascular disease. However, there is disagreement as to the existence of adverse effects of statin administration on cognitive function. Therefore, it is important to better understand the effects of statins on cognition and possible mechanisms of these effects. Areas covered: We analyzed relevant studies of the relationship between cognitive performance and statin and usage. We included articles published between 2018 and 1992. We identified three randomized trials, one observational study and 66 case reports that provided credible evidence of statin-induced cognitive impairment. We also identified seven randomized trials and two observational studies reporting no significant evidence of statin-induced cognitive impairment. Expert opinion: We found methodological differences that may have contributed to the divergence of these results. Evaluation of all these studies indicated that statin-associated cognitive decline is a real entity. Likely mechanisms to explain the adverse effects include 1. Reduction of synthesis of coenzyme Q10 with consequent increasing oxidative stress and reduction of cerebral energy production; 2. Depletion of central nervous system myelin by inhibition of cholesterol synthesis. We conclude that statin-induced cognitive decline does exist, needs to be better recognized and requires more studies of prevention and treatment.

1 June 2018 in Heart, Lung and Circulation
Verified
Journal Article
Closed access
LBLesley A. Braun
Lesley A. Braun
RORuchong Ou
Ruchong Ou
CKChristina Kure
Christina Kure
ATAdriana Trang
Adriana Trang
FRFranklin Rosenfeldt
Franklin Rosenfeldt

1 October 2014 in Heart, Lung and Circulation
Verified
Journal Article
Closed access
LBLesley A. Braun
Lesley A. Braun
OSOndine Spitzer
Ondine Spitzer
BLBianca Levkovich
Bianca Levkovich
MBMichael Bailey
Michael Bailey
CSCathy Stanguts
Cathy Stanguts
FRFranklin Rosenfeldt
Franklin Rosenfeldt

1 February 2020 in Heart, Lung and Circulation
Verified
Journal Article
Closed access
JMJuliana van der Merwe
Juliana van der Merwe
EPEldho Paul
Eldho Paul
FRFranklin Rosenfeldt
Franklin Rosenfeldt

8 September 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
MNMadeleine Courtney Nankivell
Madeleine Courtney Nankivell
FRFranklin Rosenfeldt
Franklin Rosenfeldt
APAndrew Pipingas
Andrew Pipingas
MPMatthew Pase
Matthew Pase
JRJeffery Michael Reddan
Jeffery Michael Reddan
CSCon Stough
Con Stough
Background and Objective: With an increase in the number of older citizens in most Western countries, cognitive decline is becoming an increasingly significant issue. Numerous age-related metabolic and physiological changes, such as increased inflammation and oxidative stress, decreased adenosine triphosphate (ATP) production, poorer cardiovascular function, and reduced cerebral blood flow, have been implicated in cognitive decline, prompting research into interventions. Among these, Coenzyme Q10 (CoQ10), an antioxidant and metabolic stimulant, has shown promise in improving some of the underlying biological mechanisms of cognitive decline. However, not much is known about the efficacy of CoQ10 supplementation on cognition in the elderly. Therefore, the aim of this review is to explore the efficacy of CoQ10 supplementation on cognitive function. Methods: We conducted a review of animal studies and human clinical trials investigating the effect of CoQ10 supplementation on cognition in samples who were healthy or with specific diseases. Overall, twelve studies demonstrated improved cognitive function and two showed a reduction in oxidative stress in response to CoQ10 supplementation, either alone or in combination with other compounds. Out of eight human clinical trials in healthy subjects (n = 2) and disease states (n = 6), four showed evidence of a beneficial effect of CoQ10 supplementation on cognition, while two demonstrated an increase in cerebral blood flow. Disparity in the results of the clinical trials presented here is likely due to differing testing procedures, inconsistent use of cognitive assessments, and/or varying bioavailability of different preparations of CoQ10. Conclusions: There is some evidence to suggest that cognition and the biological mechanisms that regulate it are positively impacted by CoQ10 therapy. However, it is crucial to note that the literature presents mixed results, with many human clinical trials also reporting no benefit of CoQ10 supplementation on cognitive performance. To fully evaluate the benefits of CoQ10 on cognitive function in ageing and in neurodegenerative diseases, future studies are needed that target possible mechanisms and utilise a wider range of cognitive assessments.

1 February 2020 in Heart, Lung and Circulation
Verified
Journal Article
Closed access
HKHans-Ulrich Kloer
Hans-Ulrich Kloer
RBRomualdo Belardinelli
Romualdo Belardinelli
OROu Ruchong
Ou Ruchong
FRFranklin Rosenfeldt
Franklin Rosenfeldt